Mark Shearman - Feb 13, 2023 Form 4 Insider Report for Editas Medicine, Inc. (EDIT)

Role
EVP, CHIEF SCIENTIFIC OFFICER
Signature
/s/ Mark Shearman
Stock symbol
EDIT
Transactions as of
Feb 13, 2023
Transactions value $
-$26,966
Form type
4
Date filed
2/15/2023, 03:30 PM
Previous filing
Jun 16, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % Price $ Shares After Date Ownership Footnotes
transaction EDIT Common Stock -Sell -$26,966 -2,790 -4.08% $9.67 65,559 Feb 13, 2023 Direct F1

Explanation of Responses:

Id Content
F1 Sale was effected pursuant to a durable automatic sales instruction plan adopted by the Reporting Person on April 19, 2021 and represents the sale of shares necessary to meet tax withholding obligations as a result of vesting in restricted stock units on February 10, 2023. The sale does not represent a discretionary trade by the Reporting Person.